Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06806852 · ClinicalTrials.gov registry record · Phase 1
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
A Phase 1 study of Head and Neck Squamous Cell Carcinoma, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT06806852 is a Phase 1 study of Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 90 participants, below the 116-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06806852, a Phase 1 study of Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 770371 and pembrolizumab may help the immune system fight cancer. Cetuximab blocks growth signals and may prevent the tumor from growing. Participants are put into 3 groups randomly. Each group receives a different combination of study medicines. All study medicines are given as an infusion into a vein at the study site. Participants can stay in the study as long as they benefit from treatment. Doctors regularly check the size of the tumor and check whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cetuximab
- DRUG BI 770371
Study Locations (20)
Other
- Hospital de Amor - Barretos
- Liga Norte Riograndense contra o cancer - Natal
- Fundação Faculdade Regional de Medicina de São José do Rio Preto - São José do Rio Preto
- MBAL Sveta Sofia - Sofia
- CTR Oscar Lambret - Lille
- CTR Leon Berard - Lyon
- HOP Timone - Marseille
- Institut Gustave Roussy - Villejuif
- ARENSIA Exploratory Medicine LLC - Tbilisi
- Städtisches Klinikum Braunschweig gGmbH - Braunschweig
- Universitätsklinikum Jena - Jena
- Universität Leipzig - Leipzig
- Universitätsklinikum Ulm - Ulm
- Semmelweis University - Budapest
- National Institute of Oncology - Budapest
Kentucky
- Norton Cancer Institute, Downtown - Louisville
Minnesota
- M Health Fairview Clinics and Surgery Center - Minneapolis - Minneapolis
Ohio
- The Ohio State University Wexner Medical Center - Columbus
New South Wales
- Gosford Hospital - Gosford
Victoria
- Andrew Love Cancer Centre - Geelong
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06806852
The ClinicalTrials.gov registry entry for NCT06806852 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (22% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06806852 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Kentucky, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06806852 about?
NCT06806852 is a clinical study titled "A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone". This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 77037...
What is the current status of trial NCT06806852?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-05-14. Estimated completion is 2027-07-31.
What conditions does trial NCT06806852 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06806852?
The interventions under investigation include: Pembrolizumab (DRUG), Cetuximab (DRUG), BI 770371 (DRUG).
Who is sponsoring clinical trial NCT06806852?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06806852 being conducted?
This trial has 20 study locations across Kentucky, Minnesota, Ohio, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RECRUITING · Phase 1
-
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RECRUITING · Phase 1
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.